CleftGeneDB-Search

Gene: INHBA

Basic information

Tag	Content
Uniprot ID	P08476; Q14599;
Entrez ID	3624
Genbank protein ID	CAA40805.1; CAA40806.1; AAA59168.1; CAA51163.1; CAA28041.1; AAA35787.1; AAQ96861.1; AAH07858.1;
Genbank nucleotide ID	NM_002192.3; XM_017012176.1;
Ensembl protein ID	ENSP00000490646; ENSP00000242208; ENSP00000397197;
Ensembl nucleotide ID	ENSG00000122641
Gene name	Inhibin beta A chain
Gene symbol	INHBA
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins.
Sequence	MPLLWLRGFL LASCWIIVRS SPTPGSEGHS AAPDCPSCAL AALPKDVPNS QPEMVEAVKK 60 HILNMLHLKK RPDVTQPVPK AALLNAIRKL HVGKVGENGY VEIEDDIGRR AEMNELMEQT 120 SEIITFAESG TARKTLHFEI SKEGSDLSVV ERAEVWLFLK VPKANRTRTK VTIRLFQQQK 180 HPQGSLDTGE EAEEVGLKGE RSELLLSEKV VDARKSTWHV FPVSSSIQRL LDQGKSSLDV 240 RIACEQCQES GASLVLLGKK KKKEEEGEGK KKGGGEGGAG ADEEKEQSHR PFLMLQARQS 300 EDHPHRRRRR GLECDGKVNI CCKKQFFVSF KDIGWNDWII APSGYHANYC EGECPSHIAG 360 TSGSSLSFHS TVINHYRMRG HSPFANLKSC CVPTKLRPMS MLYYDDGQNI IKKDIQNMIV 420 EECGCS 426

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1NYS
1NYU
1S4Y
2ARP
2ARV
2B0U
2P6A
3B4V
4MID
5HLY
5HLZ
2ARP
2ARV
2B0U
2P6A

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Developmental stage	Species	Evidence	Details
1:1 ortholog	INHBA	281867	P07995			Bos taurus	Prediction	More>>
1:1 ortholog	INHBA	483245	E2QW13			Canis lupus familiaris	Prediction	More>>
1:1 ortholog	INHBA	100860960	F8SXW5			Capra hircus	Prediction	More>>
1:1 ortholog	INHBA	3624	P08476			Homo sapiens	Prediction	More>>
1:1 ortholog	Inhba	16323	Q04998	CPO	E12.5	Mus musculus	Publication	More>>
1:1 ortholog	INHBA	463371	H2QUH0			Pan troglodytes	Prediction	More>>
1:1 ortholog	INHBA	397093	P03970			Sus scrofa	Prediction	More>>
1:1 ortholog	Inhba	29200	P18331			Rattus norvegicus	Prediction	More>>
1:1 ortholog	inhbaa	30072	Q8QGE3			Danio rerio	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs1366906380	p.Trp5Cys	missense variant	-	NC_000007.14:g.41700360C>A	gnomAD
rs1164410355	p.Gly8Glu	missense variant	-	NC_000007.14:g.41700352C>T	gnomAD
rs1156510703	p.Gly8Arg	missense variant	-	NC_000007.14:g.41700353C>T	TOPMed
rs1429366494	p.Phe9Leu	missense variant	-	NC_000007.14:g.41700348A>C	gnomAD
NCI-TCGA novel	p.Ala12Thr	missense variant	-	NC_000007.14:g.41700341C>T	NCI-TCGA
rs1488241309	p.Ala12Ser	missense variant	-	NC_000007.14:g.41700341C>A	gnomAD
rs777959895	p.Cys14Tyr	missense variant	-	NC_000007.14:g.41700334C>T	ExAC,gnomAD
rs777959895	p.Cys14Phe	missense variant	-	NC_000007.14:g.41700334C>A	ExAC,gnomAD
rs149209111	p.Cys14Ser	missense variant	-	NC_000007.14:g.41700335A>T	ESP,TOPMed
NCI-TCGA novel	p.Trp15Arg	missense variant	-	NC_000007.14:g.41700332A>T	NCI-TCGA
rs933197708	p.Trp15Cys	missense variant	-	NC_000007.14:g.41700330C>A	TOPMed
rs758814874	p.Ile16Thr	missense variant	-	NC_000007.14:g.41700328A>G	ExAC,gnomAD
NCI-TCGA novel	p.Val18Leu	missense variant	-	NC_000007.14:g.41700323C>A	NCI-TCGA
COSM3923617	p.Ser21Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700313G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Thr23ProPheSerTerUnkUnk	frameshift	-	NC_000007.14:g.41700309G>-	NCI-TCGA
rs765780968	p.Pro24Leu	missense variant	-	NC_000007.14:g.41700304G>A	ExAC,gnomAD
rs1444327391	p.Pro24Ala	missense variant	-	NC_000007.14:g.41700305G>C	TOPMed
NCI-TCGA novel	p.Gly25Ter	stop gained	-	NC_000007.14:g.41700302C>A	NCI-TCGA
rs755619740	p.Ser26Phe	missense variant	-	NC_000007.14:g.41700298G>A	ExAC,TOPMed,gnomAD
rs1372354341	p.Glu27Gln	missense variant	-	NC_000007.14:g.41700296C>G	TOPMed
rs972161023	p.Gly28Glu	missense variant	-	NC_000007.14:g.41700292C>T	gnomAD
NCI-TCGA novel	p.Gly28Arg	missense variant	-	NC_000007.14:g.41700293C>T	NCI-TCGA
rs534590694	p.His29Asp	missense variant	-	NC_000007.14:g.41700290G>C	1000Genomes,ExAC,gnomAD
rs534590694	p.His29Tyr	missense variant	-	NC_000007.14:g.41700290G>A	1000Genomes,ExAC,gnomAD
COSM3638689	p.Ser30Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700286C>T	NCI-TCGA Cosmic
rs942081109	p.Ser30Arg	missense variant	-	NC_000007.14:g.41700285G>T	-
rs1283898685	p.Ala31Pro	missense variant	-	NC_000007.14:g.41700284C>G	gnomAD
rs761497837	p.Ala31Val	missense variant	-	NC_000007.14:g.41700283G>A	ExAC,TOPMed,gnomAD
rs376838491	p.Ala32Thr	missense variant	-	NC_000007.14:g.41700281C>T	ESP,ExAC,TOPMed,gnomAD
rs1488136875	p.Ala32Gly	missense variant	-	NC_000007.14:g.41700280G>C	gnomAD
rs762816927	p.Pro33Thr	missense variant	-	NC_000007.14:g.41700278G>T	ExAC,gnomAD
rs1261664857	p.Asp34Asn	missense variant	-	NC_000007.14:g.41700275C>T	gnomAD
rs201591674	p.Pro36Arg	missense variant	-	NC_000007.14:g.41700268G>C	ExAC,gnomAD
COSM1089620	p.Ala39Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700259G>A	NCI-TCGA Cosmic
rs373520349	p.Ala39Glu	missense variant	-	NC_000007.14:g.41700259G>T	ESP,ExAC,TOPMed,gnomAD
rs1232597234	p.Leu40Pro	missense variant	-	NC_000007.14:g.41700256A>G	TOPMed
rs771248041	p.Leu40Val	missense variant	-	NC_000007.14:g.41700257G>C	ExAC,gnomAD
rs373322295	p.Ala41Val	missense variant	-	NC_000007.14:g.41700253G>A	ESP,ExAC,TOPMed,gnomAD
rs984438766	p.Ala41Thr	missense variant	-	NC_000007.14:g.41700254C>T	TOPMed,gnomAD
rs373322295	p.Ala41Gly	missense variant	-	NC_000007.14:g.41700253G>C	ESP,ExAC,TOPMed,gnomAD
rs376794102	p.Ala42Thr	missense variant	-	NC_000007.14:g.41700251C>T	ExAC,gnomAD
rs376794102	p.Ala42Ser	missense variant	-	NC_000007.14:g.41700251C>A	ExAC,gnomAD
rs953665038	p.Lys45Arg	missense variant	-	NC_000007.14:g.41700241T>C	TOPMed,gnomAD
rs1316814689	p.Pro48Leu	missense variant	-	NC_000007.14:g.41700232G>A	TOPMed,gnomAD
rs1316814689	p.Pro48His	missense variant	-	NC_000007.14:g.41700232G>T	TOPMed,gnomAD
rs1235277612	p.Asn49Ser	missense variant	-	NC_000007.14:g.41700229T>C	gnomAD
rs779271157	p.Ser50Tyr	missense variant	-	NC_000007.14:g.41700226G>T	ExAC,gnomAD
rs779271157	p.Ser50Cys	missense variant	-	NC_000007.14:g.41700226G>C	ExAC,gnomAD
COSM1450706	p.Pro52Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700221G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Pro52Gln	missense variant	-	NC_000007.14:g.41700220G>T	NCI-TCGA
rs1030538647	p.Met54Ile	missense variant	-	NC_000007.14:g.41700213C>A	TOPMed
NCI-TCGA novel	p.Glu56Asp	missense variant	-	NC_000007.14:g.41700207C>A	NCI-TCGA
NCI-TCGA novel	p.Ala57Val	missense variant	-	NC_000007.14:g.41700205G>A	NCI-TCGA
rs1329616704	p.Val58Leu	missense variant	-	NC_000007.14:g.41700203C>G	gnomAD
rs749899848	p.His61Tyr	missense variant	-	NC_000007.14:g.41700194G>A	ExAC,gnomAD
NCI-TCGA novel	p.Asn64Lys	missense variant	-	NC_000007.14:g.41700183G>C	NCI-TCGA
rs1441973969	p.Arg71Ser	missense variant	-	NC_000007.14:g.41700162T>G	gnomAD
rs751118764	p.Pro72His	missense variant	-	NC_000007.14:g.41700160G>T	ExAC,gnomAD
rs762653354	p.Asp73Asn	missense variant	-	NC_000007.14:g.41700158C>T	ExAC,gnomAD
NCI-TCGA novel	p.Val74Ala	missense variant	-	NC_000007.14:g.41700154A>G	NCI-TCGA
rs182017908	p.Thr75Ser	missense variant	-	NC_000007.14:g.41700151G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs752596382	p.Thr75Pro	missense variant	-	NC_000007.14:g.41700152T>G	ExAC,gnomAD
rs182017908	p.Thr75Ile	missense variant	-	NC_000007.14:g.41700151G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs776731486	p.Gln76Ter	stop gained	-	NC_000007.14:g.41700149G>A	ExAC
NCI-TCGA novel	p.Gln76His	missense variant	-	NC_000007.14:g.41700147C>A	NCI-TCGA
NCI-TCGA novel	p.Pro77Ala	missense variant	-	NC_000007.14:g.41700146G>C	NCI-TCGA
rs771076354	p.Val78Ile	missense variant	-	NC_000007.14:g.41700143C>T	ExAC,TOPMed,gnomAD
rs760840635	p.Pro79Ser	missense variant	-	NC_000007.14:g.41700140G>A	ExAC,gnomAD
NCI-TCGA novel	p.Pro79Leu	missense variant	-	NC_000007.14:g.41700139G>A	NCI-TCGA
rs1339554915	p.Lys80Thr	missense variant	-	NC_000007.14:g.41700136T>G	gnomAD
COSM1089617	p.Ala81Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700133G>A	NCI-TCGA Cosmic
COSM6177881	p.Ala81Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700133G>T	NCI-TCGA Cosmic
COSM3880978	p.Ala82Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700130G>A	NCI-TCGA Cosmic
rs1446232934	p.Ala82Thr	missense variant	-	NC_000007.14:g.41700131C>T	gnomAD
rs748436551	p.Leu83Val	missense variant	-	NC_000007.14:g.41700128G>C	ExAC,gnomAD
rs779371975	p.Asn85Ser	missense variant	-	NC_000007.14:g.41700121T>C	ExAC,TOPMed,gnomAD
rs749750926	p.Ala86Val	missense variant	-	NC_000007.14:g.41700118G>A	ExAC,gnomAD
rs756693243	p.Ile87Met	missense variant	-	NC_000007.14:g.41700114G>C	ExAC,gnomAD
rs777279223	p.His91Arg	missense variant	-	NC_000007.14:g.41700103T>C	ExAC,gnomAD
rs752403730	p.Val95Ile	missense variant	-	NC_000007.14:g.41700092C>T	ExAC,gnomAD
rs540086083	p.Glu97Gln	missense variant	-	NC_000007.14:g.41700086C>G	1000Genomes,ExAC,gnomAD
NCI-TCGA novel	p.Glu97Asp	missense variant	-	NC_000007.14:g.41700084C>A	NCI-TCGA
rs149702280	p.Asn98Lys	missense variant	-	NC_000007.14:g.41700081G>T	ESP,ExAC,TOPMed,gnomAD
rs773386945	p.Tyr100Asn	missense variant	-	NC_000007.14:g.41700077A>T	ExAC,gnomAD
rs1476143414	p.Asp105Tyr	missense variant	-	NC_000007.14:g.41700062C>A	TOPMed
COSM1131585	p.Ile107Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700055A>T	NCI-TCGA Cosmic
rs1001765662	p.Ile107Ser	missense variant	-	NC_000007.14:g.41700055A>C	TOPMed
rs1001765662	p.Ile107Thr	missense variant	-	NC_000007.14:g.41700055A>G	TOPMed
NCI-TCGA novel	p.Gly108Glu	missense variant	-	NC_000007.14:g.41700052C>T	NCI-TCGA
rs551268437	p.Gly108Arg	missense variant	-	NC_000007.14:g.41700053C>T	1000Genomes,ExAC,gnomAD
rs1339899817	p.Ala111Glu	missense variant	-	NC_000007.14:g.41700043G>T	gnomAD
NCI-TCGA novel	p.Glu112Ter	stop gained	-	NC_000007.14:g.41700041C>A	NCI-TCGA
rs768954945	p.Met113Val	missense variant	-	NC_000007.14:g.41700038T>C	ExAC,gnomAD
COSM746913	p.Glu115Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700032C>G	NCI-TCGA Cosmic
COSM1254835	p.Leu116Pro	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700028A>G	NCI-TCGA Cosmic
COSM1450705	p.Leu116Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700028A>C	NCI-TCGA Cosmic
rs780538034	p.Leu116Phe	missense variant	-	NC_000007.14:g.41700029G>A	ExAC,gnomAD
rs777383877	p.Met117Thr	missense variant	-	NC_000007.14:g.41700025A>G	ExAC,TOPMed,gnomAD
rs746480596	p.Met117Val	missense variant	-	NC_000007.14:g.41700026T>C	ExAC
COSM3638688	p.Glu118Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41700023C>T	NCI-TCGA Cosmic
rs747778899	p.Gln119Glu	missense variant	-	NC_000007.14:g.41700020G>C	ExAC,gnomAD
rs778711643	p.Thr120Ile	missense variant	-	NC_000007.14:g.41700016G>A	ExAC,gnomAD
NCI-TCGA novel	p.Glu122Asp	missense variant	-	NC_000007.14:g.41700009C>A	NCI-TCGA
rs1261026870	p.Glu128Gln	missense variant	-	NC_000007.14:g.41699993C>G	gnomAD
NCI-TCGA novel	p.Gly130Arg	missense variant	-	NC_000007.14:g.41699987C>T	NCI-TCGA
rs764280388	p.Thr131Ile	missense variant	-	NC_000007.14:g.41690539G>A	ExAC,TOPMed,gnomAD
rs1369747479	p.Ala132Asp	missense variant	-	NC_000007.14:g.41690536G>T	TOPMed,gnomAD
rs763203259	p.Arg133Lys	missense variant	-	NC_000007.14:g.41690533C>T	ExAC,gnomAD
rs765588441	p.Lys134Glu	missense variant	-	NC_000007.14:g.41690531T>C	ExAC,TOPMed,gnomAD
rs142519810	p.Thr135Met	missense variant	-	NC_000007.14:g.41690527G>A	ESP,ExAC,TOPMed,gnomAD
COSM6177882	p.Glu139Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690514C>G	NCI-TCGA Cosmic
NCI-TCGA novel	p.Glu139Lys	missense variant	-	NC_000007.14:g.41690516C>T	NCI-TCGA
rs139371691	p.Glu139Ala	missense variant	-	NC_000007.14:g.41690515T>G	ESP,ExAC,TOPMed,gnomAD
COSM4820280	p.Ile140Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690512A>G	NCI-TCGA Cosmic
COSM3638685	p.Ser141Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690509G>A	NCI-TCGA Cosmic
COSM6177883	p.Lys142Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690505C>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Glu143Lys	missense variant	-	NC_000007.14:g.41690504C>T	NCI-TCGA
rs1221555253	p.Glu143Ala	missense variant	-	NC_000007.14:g.41690503T>G	TOPMed
NCI-TCGA novel	p.Gly144Asp	missense variant	-	NC_000007.14:g.41690500C>T	NCI-TCGA
rs979257752	p.Asp146Asn	missense variant	-	NC_000007.14:g.41690495C>T	gnomAD
NCI-TCGA novel	p.Glu151Gln	missense variant	-	NC_000007.14:g.41690480C>G	NCI-TCGA
rs377167564	p.Arg152His	missense variant	-	NC_000007.14:g.41690476C>T	ESP,ExAC,TOPMed,gnomAD
rs748897120	p.Arg152Cys	missense variant	-	NC_000007.14:g.41690477G>A	ExAC,gnomAD
rs377167564	p.Arg152Leu	missense variant	-	NC_000007.14:g.41690476C>A	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Glu154Lys	missense variant	-	NC_000007.14:g.41690471C>T	NCI-TCGA
COSM1089616	p.Trp156Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000007.14:g.41690464C>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Trp156Ter	stop gained	-	NC_000007.14:g.41690463C>T	NCI-TCGA
rs769570431	p.Leu159Val	missense variant	-	NC_000007.14:g.41690456G>C	ExAC,gnomAD
NCI-TCGA novel	p.Val161SerPheSerTerUnkUnk	frameshift	-	NC_000007.14:g.41690451T>-	NCI-TCGA
rs1354806996	p.Val161Phe	missense variant	-	NC_000007.14:g.41690450C>A	gnomAD
COSM3638684	p.Pro162Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690447G>A	NCI-TCGA Cosmic
COSM3880976	p.Pro162His	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690446G>T	NCI-TCGA Cosmic
rs1397640362	p.Pro162Leu	missense variant	-	NC_000007.14:g.41690446G>A	gnomAD
rs373733975	p.Ala164Thr	missense variant	-	NC_000007.14:g.41690441C>T	ESP,ExAC,gnomAD
rs1374218408	p.Arg166Ser	missense variant	-	NC_000007.14:g.41690433C>A	TOPMed,gnomAD
rs781179854	p.Arg166Trp	missense variant	-	NC_000007.14:g.41690435T>A	ExAC,gnomAD
COSM3638683	p.Arg168Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690428C>T	NCI-TCGA Cosmic
rs777791358	p.Lys170Ile	missense variant	-	NC_000007.14:g.41690422T>A	ExAC,TOPMed,gnomAD
rs777791358	p.Lys170Thr	missense variant	-	NC_000007.14:g.41690422T>G	ExAC,TOPMed,gnomAD
rs1434057860	p.Val171Ile	missense variant	-	NC_000007.14:g.41690420C>T	gnomAD
COSM601369	p.Arg174Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690411G>T	NCI-TCGA Cosmic
rs537531066	p.Arg174His	missense variant	-	NC_000007.14:g.41690410C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs758496316	p.Arg174Cys	missense variant	-	NC_000007.14:g.41690411G>A	ExAC,gnomAD
rs537531066	p.Arg174Leu	missense variant	-	NC_000007.14:g.41690410C>A	1000Genomes,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Leu175SerPheSerTerUnkUnk	frameshift	-	NC_000007.14:g.41690408G>-	NCI-TCGA
rs1182490702	p.Phe176Ile	missense variant	-	NC_000007.14:g.41690405A>T	gnomAD
COSM6110269	p.Gln177Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690402G>C	NCI-TCGA Cosmic
NCI-TCGA novel	p.Gln177His	missense variant	-	NC_000007.14:g.41690400C>G	NCI-TCGA
rs759930790	p.Gln178Arg	missense variant	-	NC_000007.14:g.41690398T>C	ExAC,gnomAD
COSM5768309	p.Gln179Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000007.14:g.41690396G>A	NCI-TCGA Cosmic
rs766876018	p.Gln179Pro	missense variant	-	NC_000007.14:g.41690395T>G	ExAC,gnomAD
rs761221455	p.Gln179His	missense variant	-	NC_000007.14:g.41690394C>A	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gln179Glu	missense variant	-	NC_000007.14:g.41690396G>C	NCI-TCGA
COSM3431597	p.Pro182Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690386G>A	NCI-TCGA Cosmic
rs766987359	p.Pro182Gln	missense variant	-	NC_000007.14:g.41690386G>T	ExAC,TOPMed,gnomAD
rs766987359	p.Pro182Arg	missense variant	-	NC_000007.14:g.41690386G>C	ExAC,TOPMed,gnomAD
rs773874254	p.Pro182Ala	missense variant	-	NC_000007.14:g.41690387G>C	ExAC,gnomAD
rs769393297	p.Gly184Ser	missense variant	-	NC_000007.14:g.41690381C>T	ExAC,gnomAD
rs868188277	p.Ser185Asn	missense variant	-	NC_000007.14:g.41690377C>T	gnomAD
rs868188277	p.Ser185Thr	missense variant	-	NC_000007.14:g.41690377C>G	gnomAD
COSM3638682	p.Asp187Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690372C>T	NCI-TCGA Cosmic
rs1380653684	p.Asp187His	missense variant	-	NC_000007.14:g.41690372C>G	TOPMed,gnomAD
rs1025790050	p.Gly189Arg	missense variant	-	NC_000007.14:g.41690366C>T	TOPMed,gnomAD
rs867739441	p.Glu190Lys	missense variant	-	NC_000007.14:g.41690363C>T	-
NCI-TCGA novel	p.Glu190Ter	stop gained	-	NC_000007.14:g.41690363C>A	NCI-TCGA
NCI-TCGA novel	p.Glu190GlnPheSerTerUnkUnk	frameshift	-	NC_000007.14:g.41690363_41690364insCCCTGTGTCCAAGCTG	NCI-TCGA
NCI-TCGA novel	p.Glu191Lys	missense variant	-	NC_000007.14:g.41690360C>T	NCI-TCGA
rs138705117	p.Glu191Asp	missense variant	-	NC_000007.14:g.41690358C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs780890864	p.Ala192Ser	missense variant	-	NC_000007.14:g.41690357C>A	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ala192Val	missense variant	-	NC_000007.14:g.41690356G>A	NCI-TCGA
rs780890864	p.Ala192Thr	missense variant	-	NC_000007.14:g.41690357C>T	ExAC,TOPMed,gnomAD
rs1007889051	p.Glu193Lys	missense variant	-	NC_000007.14:g.41690354C>T	TOPMed,gnomAD
rs1165688714	p.Glu194Gln	missense variant	-	NC_000007.14:g.41690351C>G	gnomAD
rs1165688714	p.Glu194Lys	missense variant	-	NC_000007.14:g.41690351C>T	gnomAD
rs746900962	p.Val195Glu	missense variant	-	NC_000007.14:g.41690347A>T	ExAC
rs200425294	p.Gly196Asp	missense variant	-	NC_000007.14:g.41690344C>T	ExAC,TOPMed,gnomAD
rs1425813756	p.Gly196Ser	missense variant	-	NC_000007.14:g.41690345C>T	gnomAD
rs1345043414	p.Lys198Met	missense variant	-	NC_000007.14:g.41690338T>A	TOPMed
rs111379520	p.Gly199Glu	missense variant	-	NC_000007.14:g.41690335C>T	ExAC,TOPMed,gnomAD
rs146325702	p.Gly199Arg	missense variant	-	NC_000007.14:g.41690336C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs146325702	p.Gly199Trp	missense variant	-	NC_000007.14:g.41690336C>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs146325702	p.Gly199Arg	missense variant	-	NC_000007.14:g.41690336C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs111379520	p.Gly199Ala	missense variant	-	NC_000007.14:g.41690335C>G	ExAC,TOPMed,gnomAD
rs1379000367	p.Glu200Lys	missense variant	-	NC_000007.14:g.41690333C>T	gnomAD
rs1214870637	p.Arg201Lys	missense variant	-	NC_000007.14:g.41690329C>T	gnomAD
COSM3412043	p.Ser202Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690327T>A	NCI-TCGA Cosmic
COSM4921135	p.Glu203Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000007.14:g.41690324C>A	NCI-TCGA Cosmic
COSM3923616	p.Glu203Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690324C>T	NCI-TCGA Cosmic
rs376470270	p.Leu204Arg	missense variant	-	NC_000007.14:g.41690320A>C	ESP
NCI-TCGA novel	p.Leu204Met	missense variant	-	NC_000007.14:g.41690321G>T	NCI-TCGA
rs1266432565	p.Leu206Val	missense variant	-	NC_000007.14:g.41690315G>C	gnomAD
rs1221757242	p.del209TerSerTrpArgSerValGlyAlaHisArgValAlaGlnPro	stop gained	-	NC_000007.14:g.41690306_41690307insGGGCTGGGCAACTCTATGAGCACCCACACTCCTCCACGATCA	gnomAD
rs1309932151	p.Val210Leu	missense variant	-	NC_000007.14:g.41690303C>A	gnomAD
COSM746914	p.Val211Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690300C>A	NCI-TCGA Cosmic
rs1309408013	p.Val211Ile	missense variant	-	NC_000007.14:g.41690300C>T	gnomAD
rs149369067	p.Asp212Glu	missense variant	-	NC_000007.14:g.41690295G>T	ESP,ExAC,TOPMed,gnomAD
rs762543780	p.Ala213Thr	missense variant	-	NC_000007.14:g.41690294C>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ala213Pro	missense variant	-	NC_000007.14:g.41690294C>G	NCI-TCGA
NCI-TCGA novel	p.Ala213Val	missense variant	-	NC_000007.14:g.41690293G>A	NCI-TCGA
rs762543780	p.Ala213Ser	missense variant	-	NC_000007.14:g.41690294C>A	ExAC,TOPMed,gnomAD
rs923669088	p.Arg214Trp	missense variant	-	NC_000007.14:g.41690291G>A	-
rs1043609570	p.Arg214Gln	missense variant	-	NC_000007.14:g.41690290C>T	gnomAD
NCI-TCGA novel	p.Lys215Glu	missense variant	-	NC_000007.14:g.41690288T>C	NCI-TCGA
rs759072574	p.Thr217Ser	missense variant	-	NC_000007.14:g.41690281G>C	ExAC,gnomAD
NCI-TCGA novel	p.Thr217Ile	missense variant	-	NC_000007.14:g.41690281G>A	NCI-TCGA
COSM1089615	p.Trp218Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000007.14:g.41690277C>T	NCI-TCGA Cosmic
rs776370904	p.Phe221Leu	missense variant	-	NC_000007.14:g.41690268G>C	ExAC,gnomAD
rs770655825	p.Pro222Ser	missense variant	-	NC_000007.14:g.41690267G>A	ExAC,gnomAD
rs138819536	p.Arg229Pro	missense variant	-	NC_000007.14:g.41690245C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs138819536	p.Arg229Gln	missense variant	-	NC_000007.14:g.41690245C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs908163566	p.Arg229Trp	missense variant	-	NC_000007.14:g.41690246G>A	TOPMed
rs1489240461	p.Leu230Met	missense variant	-	NC_000007.14:g.41690243A>T	gnomAD
rs748226962	p.Leu231Met	missense variant	-	NC_000007.14:g.41690240G>T	ExAC,TOPMed,gnomAD
rs980571220	p.Gln233Glu	missense variant	-	NC_000007.14:g.41690234G>C	TOPMed,gnomAD
NCI-TCGA novel	p.Gln233Ter	stop gained	-	NC_000007.14:g.41690234G>A	NCI-TCGA
rs778816816	p.Ser236Gly	missense variant	-	NC_000007.14:g.41690225T>C	ExAC,gnomAD
rs1229001644	p.Val240Phe	missense variant	-	NC_000007.14:g.41690213C>A	TOPMed
rs1229001644	p.Val240Ile	missense variant	-	NC_000007.14:g.41690213C>T	TOPMed
rs150182559	p.Arg241Trp	missense variant	-	NC_000007.14:g.41690210G>A	ESP,ExAC,TOPMed,gnomAD
rs756546726	p.Arg241Gln	missense variant	-	NC_000007.14:g.41690209C>T	ExAC,gnomAD
COSM6110271	p.Cys244Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690200C>T	NCI-TCGA Cosmic
rs1365746909	p.Glu245Lys	missense variant	-	NC_000007.14:g.41690198C>T	TOPMed,gnomAD
rs1365746909	p.Glu245Gln	missense variant	-	NC_000007.14:g.41690198C>G	TOPMed,gnomAD
COSM6177885	p.Gln246Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690194T>A	NCI-TCGA Cosmic
rs757882910	p.Gln246His	missense variant	-	NC_000007.14:g.41690193C>G	ExAC,gnomAD
rs752140467	p.Gln248Arg	missense variant	-	NC_000007.14:g.41690188T>C	ExAC,gnomAD
rs764604932	p.Ser250Asn	missense variant	-	NC_000007.14:g.41690182C>T	ExAC,gnomAD
rs1168655188	p.Gly251Cys	missense variant	-	NC_000007.14:g.41690180C>A	gnomAD
COSM1089613	p.Ala252Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690177C>T	NCI-TCGA Cosmic
rs1378762087	p.Ala252Ser	missense variant	-	NC_000007.14:g.41690177C>A	gnomAD
rs1290822028	p.Ala252Asp	missense variant	-	NC_000007.14:g.41690176G>T	TOPMed
rs1163090037	p.Val255Phe	missense variant	-	NC_000007.14:g.41690168C>A	gnomAD
NCI-TCGA novel	p.Val255Gly	missense variant	-	NC_000007.14:g.41690167A>C	NCI-TCGA
COSM3638675	p.Leu256Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690165G>A	NCI-TCGA Cosmic
rs1192011470	p.Leu257Pro	missense variant	-	NC_000007.14:g.41690161A>G	TOPMed
COSM1450702	p.Gly258Arg	insertion	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690155_41690156insTCC	NCI-TCGA Cosmic
rs1431859332	p.Gly258Val	missense variant	-	NC_000007.14:g.41690158C>A	TOPMed,gnomAD
rs1431859332	p.Gly258Asp	missense variant	-	NC_000007.14:g.41690158C>T	TOPMed,gnomAD
rs1178685586	p.Gly258Ser	missense variant	-	NC_000007.14:g.41690159C>T	gnomAD
rs1450176512	p.Lys259Glu	missense variant	-	NC_000007.14:g.41690156T>C	TOPMed
NCI-TCGA novel	p.Lys261Asn	missense variant	-	NC_000007.14:g.41690148C>G	NCI-TCGA
NCI-TCGA novel	p.Lys262Met	missense variant	-	NC_000007.14:g.41690146T>A	NCI-TCGA
COSM281930	p.Glu264Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000007.14:g.41690141C>A	NCI-TCGA Cosmic
rs1371913954	p.Glu265Lys	missense variant	-	NC_000007.14:g.41690138C>T	TOPMed
rs1192544869	p.Glu265Gly	missense variant	-	NC_000007.14:g.41690137T>C	gnomAD
COSM6110272	p.Gly267Trp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690132C>A	NCI-TCGA Cosmic
rs760441012	p.Gly267Arg	missense variant	-	NC_000007.14:g.41690132C>T	ExAC,gnomAD
NCI-TCGA novel	p.Gly267Val	missense variant	-	NC_000007.14:g.41690131C>A	NCI-TCGA
rs1193620503	p.Gly267Ala	missense variant	-	NC_000007.14:g.41690131C>G	gnomAD
NCI-TCGA novel	p.Glu268LysPheSerTerUnkUnk	frameshift	-	NC_000007.14:g.41690129C>-	NCI-TCGA
rs779220866	p.Gly269Glu	missense variant	-	NC_000007.14:g.41690125C>T	TOPMed,gnomAD
rs779220866	p.Gly269Val	missense variant	-	NC_000007.14:g.41690125C>A	TOPMed,gnomAD
rs771884298	p.Lys271Arg	missense variant	-	NC_000007.14:g.41690119T>C	ExAC,TOPMed,gnomAD
rs1390115330	p.Lys272Arg	missense variant	-	NC_000007.14:g.41690116T>C	TOPMed
NCI-TCGA novel	p.Gly273AlaPheSerTerUnkUnk	frameshift	-	NC_000007.14:g.41690113C>-	NCI-TCGA
rs1435204559	p.Gly273Ser	missense variant	-	NC_000007.14:g.41690114C>T	TOPMed
COSM321011	p.Gly274Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690110C>A	NCI-TCGA Cosmic
rs569482596	p.Gly274Glu	missense variant	-	NC_000007.14:g.41690110C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs768547360	p.Gly274Arg	missense variant	-	NC_000007.14:g.41690111C>T	ExAC,TOPMed,gnomAD
rs780414158	p.Gly275Ser	missense variant	-	NC_000007.14:g.41690108C>T	ExAC,gnomAD
rs1355421314	p.Glu276Lys	missense variant	-	NC_000007.14:g.41690105C>T	TOPMed
rs1390964419	p.Gly277Ser	missense variant	-	NC_000007.14:g.41690102C>T	gnomAD
rs1191953816	p.Gly278Glu	missense variant	-	NC_000007.14:g.41690098C>T	gnomAD
COSM485325	p.Ala279Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690096C>A	NCI-TCGA Cosmic
rs1211988783	p.Ala279Val	missense variant	-	NC_000007.14:g.41690095G>A	TOPMed
rs951492435	p.Gly280Arg	missense variant	-	NC_000007.14:g.41690093C>T	TOPMed,gnomAD
VAR_072640	p.Gly280Glu	Missense	-	-	UniProt
rs1208258694	p.Asp282Asn	missense variant	-	NC_000007.14:g.41690087C>T	TOPMed
NCI-TCGA novel	p.Asp282Gly	missense variant	-	NC_000007.14:g.41690086T>C	NCI-TCGA
COSM6177887	p.Glu283Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690082C>A	NCI-TCGA Cosmic
rs1305050306	p.Glu283Gln	missense variant	-	NC_000007.14:g.41690084C>G	gnomAD
rs1488698571	p.Glu284Lys	missense variant	-	NC_000007.14:g.41690081C>T	gnomAD
rs1464988141	p.Gln287Glu	missense variant	-	NC_000007.14:g.41690072G>C	gnomAD
rs1159649174	p.Pro291Ser	missense variant	-	NC_000007.14:g.41690060G>A	gnomAD
rs1381819254	p.Met294Thr	missense variant	-	NC_000007.14:g.41690050A>G	gnomAD
NCI-TCGA novel	p.Met294Ile	missense variant	-	NC_000007.14:g.41690049C>A	NCI-TCGA
COSM1329828	p.Gln296His	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690043C>A	NCI-TCGA Cosmic
COSM4692500	p.Arg298Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690038C>T	NCI-TCGA Cosmic
rs373613637	p.Arg298Trp	missense variant	-	NC_000007.14:g.41690039G>A	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.His303Asn	missense variant	-	NC_000007.14:g.41690024G>T	NCI-TCGA
rs564878978	p.Arg306Gly	missense variant	-	NC_000007.14:g.41690015G>C	1000Genomes,ExAC,gnomAD
rs564878978	p.Arg306Cys	missense variant	-	NC_000007.14:g.41690015G>A	1000Genomes,ExAC,gnomAD
rs1202073030	p.Arg306His	missense variant	-	NC_000007.14:g.41690014C>T	gnomAD
rs1202073030	p.Arg306Pro	missense variant	-	NC_000007.14:g.41690014C>G	gnomAD
rs564878978	p.Arg306Ser	missense variant	-	NC_000007.14:g.41690015G>T	1000Genomes,ExAC,gnomAD
COSM1450701	p.Arg308Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690009G>A	NCI-TCGA Cosmic
COSM6177888	p.Arg309Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690005C>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Arg309Gln	missense variant	-	NC_000007.14:g.41690005C>T	NCI-TCGA
COSM1089612	p.Arg310Trp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41690003G>A	NCI-TCGA Cosmic
COSM3638671	p.Gly311Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689999C>T	NCI-TCGA Cosmic
rs35168740	p.Gly311Arg	missense variant	-	NC_000007.14:g.41690000C>G	TOPMed
rs35168740	p.Gly311Ser	missense variant	-	NC_000007.14:g.41690000C>T	TOPMed
rs772872634	p.Val318Ile	missense variant	-	NC_000007.14:g.41689979C>T	ExAC,gnomAD
rs962913455	p.Ile320Val	missense variant	-	NC_000007.14:g.41689973T>C	TOPMed,gnomAD
rs1356119994	p.Phe326Leu	missense variant	-	NC_000007.14:g.41689953G>T	TOPMed,gnomAD
NCI-TCGA novel	p.Phe330Leu	missense variant	-	NC_000007.14:g.41689941G>T	NCI-TCGA
rs138538132	p.Gly334Ser	missense variant	-	NC_000007.14:g.41689931C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs138538132	p.Gly334Cys	missense variant	-	NC_000007.14:g.41689931C>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gly334Asp	missense variant	-	NC_000007.14:g.41689930C>T	NCI-TCGA
rs768700046	p.Asn336Asp	missense variant	-	NC_000007.14:g.41689925T>C	ExAC,gnomAD
rs762923659	p.Asn336Lys	missense variant	-	NC_000007.14:g.41689923A>T	ExAC,gnomAD
NCI-TCGA novel	p.Trp338Ter	stop gained	-	NC_000007.14:g.41689918C>T	NCI-TCGA
NCI-TCGA novel	p.Trp338Arg	missense variant	-	NC_000007.14:g.41689919A>T	NCI-TCGA
rs775755149	p.Ile339Val	missense variant	-	NC_000007.14:g.41689916T>C	ExAC,gnomAD
COSM746916	p.Ala341Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689910C>T	NCI-TCGA Cosmic
COSM3638670	p.Pro342Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689906G>A	NCI-TCGA Cosmic
rs1238388233	p.Ser343Cys	missense variant	-	NC_000007.14:g.41689903G>C	TOPMed
rs1156386837	p.Tyr345Cys	missense variant	-	NC_000007.14:g.41689897T>C	gnomAD
NCI-TCGA novel	p.Ala347Val	missense variant	-	NC_000007.14:g.41689891G>A	NCI-TCGA
rs771134702	p.Asn348Ser	missense variant	-	NC_000007.14:g.41689888T>C	ExAC,gnomAD
COSM298102	p.Cys350Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689883A>G	NCI-TCGA Cosmic
RCV000709850	p.Cys350Trp	missense variant	-	NC_000007.14:g.41689881G>C	ClinVar
rs747474916	p.Pro355Arg	missense variant	-	NC_000007.14:g.41689867G>C	ExAC,gnomAD
rs747474916	p.Pro355Leu	missense variant	-	NC_000007.14:g.41689867G>A	ExAC,gnomAD
NCI-TCGA novel	p.Pro355Thr	missense variant	-	NC_000007.14:g.41689868G>T	NCI-TCGA
NCI-TCGA novel	p.Ser356Cys	missense variant	-	NC_000007.14:g.41689865T>A	NCI-TCGA
NCI-TCGA novel	p.Ser356Asn	missense variant	-	NC_000007.14:g.41689864C>T	NCI-TCGA
NCI-TCGA novel	p.Ser362Phe	missense variant	-	NC_000007.14:g.41689846G>A	NCI-TCGA
rs753232360	p.Ser364Thr	missense variant	-	NC_000007.14:g.41689841A>T	ExAC,gnomAD
NCI-TCGA novel	p.Ser364ProPheSerTerUnkUnk	frameshift	-	NC_000007.14:g.41689842C>-	NCI-TCGA
COSM5510214	p.Ser370Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689822G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Ser370Ter	stop gained	-	NC_000007.14:g.41689822G>C	NCI-TCGA
rs1357347047	p.Thr371Ile	missense variant	-	NC_000007.14:g.41689819G>A	gnomAD
COSM6110273	p.Val372Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689817C>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Ile373Met	missense variant	-	NC_000007.14:g.41689812G>C	NCI-TCGA
rs751423099	p.Tyr376His	missense variant	-	NC_000007.14:g.41689805A>G	ExAC,gnomAD
COSM1450700	p.Arg377Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689802G>A	NCI-TCGA Cosmic
COSM188210	p.Arg377His	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689801C>T	NCI-TCGA Cosmic
COSM3229806	p.Arg379Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689795C>T	NCI-TCGA Cosmic
COSM188209	p.Arg379Trp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689796G>A	NCI-TCGA Cosmic
rs1361746138	p.His381Arg	missense variant	-	NC_000007.14:g.41689789T>C	gnomAD
NCI-TCGA novel	p.His381Asn	missense variant	-	NC_000007.14:g.41689790G>T	NCI-TCGA
NCI-TCGA novel	p.His381IlePheSerTerUnkUnk	frameshift	-	NC_000007.14:g.41689790G>-	NCI-TCGA
NCI-TCGA novel	p.Ser382AlaPheSerTerUnkUnk	frameshift	-	NC_000007.14:g.41689787T>-	NCI-TCGA
rs376722349	p.Ser382Arg	missense variant	-	NC_000007.14:g.41689785G>C	ESP,ExAC,TOPMed,gnomAD
rs1157959739	p.Pro383Leu	missense variant	-	NC_000007.14:g.41689783G>A	TOPMed
rs1318105737	p.Pro383Thr	missense variant	-	NC_000007.14:g.41689784G>T	gnomAD
COSM1450697	p.Ala385Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689778C>A	NCI-TCGA Cosmic
rs1399739221	p.Asn386Lys	missense variant	-	NC_000007.14:g.41689773G>T	gnomAD
rs1361491625	p.Asn386Ser	missense variant	-	NC_000007.14:g.41689774T>C	TOPMed
rs759695534	p.Lys388Arg	missense variant	-	NC_000007.14:g.41689768T>C	ExAC,gnomAD
NCI-TCGA novel	p.Ser389IlePheSerTerUnkUnk	frameshift	-	NC_000007.14:g.41689766_41689767insT	NCI-TCGA
NCI-TCGA novel	p.Thr394Ser	missense variant	-	NC_000007.14:g.41689751T>A	NCI-TCGA
rs771243659	p.Lys395Arg	missense variant	-	NC_000007.14:g.41689747T>C	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Arg397Lys	missense variant	-	NC_000007.14:g.41689741C>T	NCI-TCGA
rs747304324	p.Pro398Ser	missense variant	-	NC_000007.14:g.41689739G>A	ExAC,gnomAD
NCI-TCGA novel	p.Ser400Pro	missense variant	-	NC_000007.14:g.41689733A>G	NCI-TCGA
COSM746917	p.Asp405Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689718C>T	NCI-TCGA Cosmic
rs1374850253	p.Asp406Ala	missense variant	-	NC_000007.14:g.41689714T>G	TOPMed
rs772344962	p.Gly407Cys	missense variant	-	NC_000007.14:g.41689712C>A	ExAC,TOPMed,gnomAD
rs772344962	p.Gly407Ser	missense variant	-	NC_000007.14:g.41689712C>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Lys412Arg	missense variant	-	NC_000007.14:g.41689696T>C	NCI-TCGA
NCI-TCGA novel	p.Asp414His	missense variant	-	NC_000007.14:g.41689691C>G	NCI-TCGA
rs779393124	p.Asp414Tyr	missense variant	-	NC_000007.14:g.41689691C>A	ExAC,gnomAD
COSM3880972	p.Asn417Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689681T>C	NCI-TCGA Cosmic
NCI-TCGA novel	p.Asn417His	missense variant	-	NC_000007.14:g.41689682T>G	NCI-TCGA
NCI-TCGA novel	p.Met418Leu	missense variant	-	NC_000007.14:g.41689679T>A	NCI-TCGA
rs749989847	p.Val420Met	missense variant	-	NC_000007.14:g.41689673C>T	ExAC,gnomAD
COSM3923615	p.Glu421Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689670C>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Gly424Val	missense variant	-	NC_000007.14:g.41689660C>A	NCI-TCGA
NCI-TCGA novel	p.Cys425Tyr	missense variant	-	NC_000007.14:g.41689657C>T	NCI-TCGA
COSM4807994	p.Ser426Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000007.14:g.41689655A>T	NCI-TCGA Cosmic

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001418	Adenocarcinoma	group	LHGDN
C0003130	Anoxia	phenotype	LHGDN
C0003873	Rheumatoid Arthritis	disease	BEFREE
C0004763	Barrett Esophagus	disease	BEFREE
C0006625	Cachexia	phenotype	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	LHGDN
C0007137	Squamous cell carcinoma	disease	LHGDN
C0007138	Carcinoma, Transitional Cell	disease	BEFREE
C0008479	Chondrosarcoma	disease	LHGDN
C0011334	Dental caries	disease	BEFREE
C0013537	Eclampsia	disease	BEFREE
C0014170	Endometrial Neoplasms	group	LHGDN
C0014175	Endometriosis	disease	BEFREE
C0015625	Fanconi Anemia	disease	BEFREE
C0022548	Keloid	phenotype	BEFREE
C0022735	Klinefelter Syndrome	disease	LHGDN
C0023267	Fibroid Tumor	group	CTD_human
C0023440	Acute Erythroblastic Leukemia	disease	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0027051	Myocardial Infarction	disease	LHGDN
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0029408	Degenerative polyarthritis	disease	BEFREE
C0029925	Ovarian Carcinoma	disease	BEFREE
C0032460	Polycystic Ovary Syndrome	disease	LHGDN
C0032914	Pre-Eclampsia	phenotype	CTD_human;LHGDN
C0035435	Rheumatism	disease	BEFREE
C0036341	Schizophrenia	disease	GWASCAT
C0042133	Uterine Fibroids	group	CTD_human
C0042138	Uterine Neoplasms	group	CTD_human
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0153567	Uterine Cancer	disease	CTD_human
C0153676	Secondary malignant neoplasm of lung	disease	BEFREE
C0162557	Liver Failure, Acute	disease	CTD_human
C0178874	Tumor Progression	phenotype	BEFREE
C0206650	Fibroadenoma	disease	LHGDN
C0206681	Adenocarcinoma, Clear Cell	disease	LHGDN
C0333519	Caries (morphologic abnormality)	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0948216	Ovarian adenocarcinoma	disease	ORPHANET
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1275122	Familial multiple trichoepitheliomata	disease	BEFREE
C1511789	Desmoplastic	disease	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C2145472	Urothelial Carcinoma	disease	BEFREE
C2239176	Liver carcinoma	disease	LHGDN
C3469521	FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)	disease	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0005125	cytokine activity	IBA
GO:0005125	cytokine activity	IDA
GO:0005179	hormone activity	TAS
GO:0005515	protein binding	IPI
GO:0008083	growth factor activity	TAS
GO:0017046	peptide hormone binding	IPI
GO:0034711	inhibin binding	IEA
GO:0042802	identical protein binding	IPI
GO:0044877	protein-containing complex binding	IEA
GO:0070699	type II activin receptor binding	IPI

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000082	G1/S transition of mitotic cell cycle	IDA
GO:0001541	ovarian follicle development	IGI
GO:0001541	ovarian follicle development	NAS
GO:0001942	hair follicle development	IGI
GO:0002244	hematopoietic progenitor cell differentiation	IDA
GO:0006357	regulation of transcription by RNA polymerase II	IDA
GO:0006952	defense response	TAS
GO:0007050	cell cycle arrest	IDA
GO:0007166	cell surface receptor signaling pathway	TAS
GO:0007267	cell-cell signaling	TAS
GO:0007399	nervous system development	NAS
GO:0008285	negative regulation of cell population proliferation	IDA
GO:0008584	male gonad development	IGI
GO:0010628	positive regulation of gene expression	IDA
GO:0010862	positive regulation of pathway-restricted SMAD protein phosphorylation	IDA
GO:0010862	positive regulation of pathway-restricted SMAD protein phosphorylation	IBA
GO:0021773	striatal medium spiny neuron differentiation	IDA
GO:0030154	cell differentiation	TAS
GO:0030218	erythrocyte differentiation	NAS
GO:0030308	negative regulation of cell growth	IDA
GO:0032270	positive regulation of cellular protein metabolic process	IDA
GO:0032924	activin receptor signaling pathway	IDA
GO:0035987	endodermal cell differentiation	IDA
GO:0042326	negative regulation of phosphorylation	TAS
GO:0042476	odontogenesis	IGI
GO:0042493	response to drug	IDA
GO:0042541	hemoglobin biosynthetic process	IDA
GO:0042701	progesterone secretion	IGI
GO:0045077	negative regulation of interferon-gamma biosynthetic process	TAS
GO:0045578	negative regulation of B cell differentiation	TAS
GO:0045648	positive regulation of erythrocyte differentiation	IDA
GO:0045650	negative regulation of macrophage differentiation	TAS
GO:0045786	negative regulation of cell cycle	IDA
GO:0045893	positive regulation of transcription, DNA-templated	IDA
GO:0045944	positive regulation of transcription by RNA polymerase II	IDA
GO:0046880	regulation of follicle-stimulating hormone secretion	IGI
GO:0046881	positive regulation of follicle-stimulating hormone secretion	TAS
GO:0046882	negative regulation of follicle-stimulating hormone secretion	NAS
GO:0048333	mesodermal cell differentiation	IEA
GO:0060021	roof of mouth development	IGI
GO:0060279	positive regulation of ovulation	ISS
GO:0060395	SMAD protein signal transduction	IBA
GO:0061029	eyelid development in camera-type eye	ISS
GO:0071372	cellular response to follicle-stimulating hormone stimulus	IEA
GO:0071397	cellular response to cholesterol	IEA
GO:0097154	GABAergic neuron differentiation	IDA
GO:0097191	extrinsic apoptotic signaling pathway	IDA
GO:2001241	positive regulation of extrinsic apoptotic signaling pathway in absence of ligand	IDA
GO:0009611	response to wounding	TAS

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005576	extracellular region	IDA
GO:0005576	extracellular region	TAS
GO:0005615	extracellular space	IBA
GO:0043509	activin A complex	IDA
GO:0043512	inhibin A complex	IDA
GO:0048471	perinuclear region of cytoplasm	IEA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-1502540	Signaling by Activin	TAS
R-HSA-1502540	Signaling by Activin	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-209822	Glycoprotein hormones	TAS
R-HSA-209952	Peptide hormone biosynthesis	TAS
R-HSA-2473224	Antagonism of Activin by Follistatin	TAS
R-HSA-2980736	Peptide hormone metabolism	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-9006936	Signaling by TGF-beta family members	TAS
R-HSA-9006936	Signaling by TGF-beta family members	IEA

Drugs and compounds information

ID	Drug Name	Action	PubMed
C006718	1,12-benzoperylene	1,12-benzoperylene results in decreased expression of INHBA mRNA	26377693
C540596	1,2,5,6-tetrabromocyclooctane	1,2,5,6-tetrabromocyclooctane results in decreased expression of INHBA mRNA	25646719
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of INHBA mRNA	28903501
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of INHBA mRNA	28628672
D015655	1-Methyl-4-phenylpyridinium	INHBA protein results in decreased susceptibility to 1-Methyl-4-phenylpyridinium	7882977
D015058	1-Naphthylisothiocyanate	1-Naphthylisothiocyanate results in decreased expression of INHBA mRNA	30723492
C029790	2,2',3',4,4',5-hexachlorobiphenyl	2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of INHBA mRNA	23829299
C404910	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [FSHB protein affects the expression of INHBA mRNA]	19414516
C013186	2,3-pentanedione	2,3-pentanedione results in increased expression of INHBA mRNA	25710175
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of INHBA mRNA	23146750
C016403	2,4-dinitrotoluene	2,4-dinitrotoluene affects the expression of INHBA mRNA	21346803
C009407	2,5,2',5'-tetrachlorobiphenyl	2,5,2',5'-tetrachlorobiphenyl results in decreased expression of INHBA mRNA	23829299
C007997	25-hydroxycholesterol	25-hydroxycholesterol results in decreased expression of INHBA protein	19464342
C007997	25-hydroxycholesterol	25-hydroxycholesterol results in increased expression of INHBA mRNA	19464342
C012796	2-butenal	2-butenal results in decreased expression of INHBA mRNA	20471460
C576261	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	[bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate co-treated with 2-ethylhexyl 2,3,4,5-tetrabromobenzoate] results in decreased expression of INHBA mRNA	25461741
C029955	2-nitrotoluene	2-nitrotoluene results in decreased expression of INHBA mRNA	15618236
C002010	4-(2-aminoethyl)benzenesulfonylfluoride	4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]	20660070
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [INHBA protein results in increased expression of SERPINE1 mRNA]	22286157
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [INHBA protein results in increased expression of TF mRNA]	22286157
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [INHBA protein results in increased phosphorylation of SMAD2 protein]	20074812
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [INHBA protein results in increased secretion of IL11 protein]	20074812
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
C017572	4-nitrotoluene	4-nitrotoluene results in decreased expression of INHBA mRNA	15618236
C029370	4-toluidine	4-toluidine results in decreased expression of INHBA mRNA	27638505
D015124	8-Bromo Cyclic Adenosine Monophosphate	8-Bromo Cyclic Adenosine Monophosphate results in increased expression of INHBA mRNA	20147733; 22079614;
D015127	9,10-Dimethyl-1,2-benzanthracene	9,10-Dimethyl-1,2-benzanthracene results in increased expression of INHBA mRNA	22485181
C496492	abrine	abrine results in increased expression of INHBA mRNA	31054353
D000082	Acetaminophen	Acetaminophen results in decreased expression of INHBA mRNA	22230336; 26690555;
D000082	Acetaminophen	Acetaminophen results in increased expression of INHBA protein	12560755
D000082	Acetaminophen	Acetaminophen affects the expression of INHBA mRNA	17562736
D020106	Acrylamide	Acrylamide results in decreased expression of INHBA mRNA	28959563
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of INHBA mRNA	22100608
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of INHBA gene	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of INHBA mRNA	23630614
D000638	Amiodarone	Amiodarone results in decreased expression of INHBA mRNA	24535564
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of INHBA mRNA	16483693
D001151	Arsenic	Arsenic affects the expression of INHBA protein	24675094
D001152	Arsenicals	Arsenicals results in increased expression of INHBA mRNA	28625800
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of INHBA mRNA	20458559
C015001	arsenite	[arsenite co-treated with Benzo(a)pyrene] results in decreased expression of INHBA mRNA	15894712
C015001	arsenite	arsenite results in decreased expression of INHBA mRNA	15894712
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite affects the expression of INHBA mRNA	25757056
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite results in decreased expression of INHBA protein	23634900
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite results in increased expression of INHBA mRNA	24160326; 25351596;
D017632	Asbestos, Serpentine	Asbestos, Serpentine results in decreased expression of INHBA mRNA	24160326
D017632	Asbestos, Serpentine	Asbestos, Serpentine results in increased expression of INHBA mRNA	24160326
D001280	Atrazine	Atrazine results in decreased expression of INHBA mRNA	29505797
D001397	Azoxymethane	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INHBA mRNA	29950665
C487081	belinostat	belinostat results in increased expression of INHBA mRNA	26272509
C487081	belinostat	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
D001548	Benzalkonium Compounds	Benzalkonium Compounds results in increased expression of INHBA mRNA	30171875
D001564	Benzo(a)pyrene	[arsenite co-treated with Benzo(a)pyrene] results in decreased expression of INHBA mRNA	15894712
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of INHBA mRNA	15894712; 19770486;
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of INHBA mRNA	22228805
C576262	bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate	[bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate co-treated with 2-ethylhexyl 2,3,4,5-tetrabromobenzoate] results in decreased expression of INHBA mRNA	25461741
C543008	bis(4-hydroxyphenyl)sulfone	[bis(4-hydroxyphenyl)sulfone co-treated with Tretinoin] results in decreased expression of INHBA mRNA	30951980
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased expression of INHBA mRNA	30951980
C070515	bisindolylmaleimide I	bisindolylmaleimide I inhibits the reaction [Busulfan results in increased expression of INHBA mRNA]	12966370
C070515	bisindolylmaleimide I	bisindolylmaleimide I inhibits the reaction [Busulfan results in increased expression of INHBA protein]	12966370
C006780	bisphenol A	[bisphenol A co-treated with Tretinoin] results in decreased expression of INHBA mRNA	30951980
C006780	bisphenol A	bisphenol A results in increased expression of INHBA mRNA	30951980
C006780	bisphenol A	bisphenol A results in increased expression of INHBA mRNA	25181051
C000611646	bisphenol F	[bisphenol F co-treated with Tretinoin] results in decreased expression of INHBA mRNA	30951980
C000611646	bisphenol F	bisphenol F results in increased expression of INHBA mRNA	30951980
D002065	Buspirone	Buspirone results in decreased expression of INHBA mRNA	24136188
D002066	Busulfan	bisindolylmaleimide I inhibits the reaction [Busulfan results in increased expression of INHBA mRNA]	12966370
D002066	Busulfan	bisindolylmaleimide I inhibits the reaction [Busulfan results in increased expression of INHBA protein]	12966370
D002066	Busulfan	Busulfan results in increased expression of INHBA mRNA	12966370; 22286157;
D002066	Busulfan	Busulfan results in increased expression of INHBA protein	12966370
C018475	butyraldehyde	butyraldehyde results in increased expression of INHBA mRNA	26079696
D002104	Cadmium	Cadmium results in increased expression of INHBA mRNA	21120746; 21694771; 30125854;
D002117	Calcitriol	Calcitriol results in decreased expression of INHBA mRNA	16002434
D002117	Calcitriol	Calcitriol results in increased expression of INHBA mRNA	23589129
D002117	Calcitriol	Calcitriol results in increased expression of INHBA protein	23589129
D002117	Calcitriol	INHBA protein inhibits the reaction [Calcitriol results in increased expression of BGLAP mRNA]	23589129
D002211	Capsaicin	Capsaicin results in increased expression of INHBA protein	22150557
D002211	Capsaicin	Naproxen inhibits the reaction [Capsaicin results in increased expression of INHBA protein]	22150557
D002211	Capsaicin	Sumatriptan inhibits the reaction [Capsaicin results in increased expression of INHBA protein]	22150557
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of INHBA mRNA	12706302
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of INHBA protein	12706302
D002330	Carmustine	INHBA mRNA affects the susceptibility to Carmustine	16365179
D002713	Chlorine	[Ozone co-treated with Chlorine] results in increased expression of INHBA mRNA	18636392
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in decreased expression of INHBA mRNA	23650126
D002784	Cholesterol	Cholesterol results in increased expression of INHBA mRNA	26296894
C074702	chromium hexavalent ion	chromium hexavalent ion affects the expression of INHBA mRNA	28472532
D002922	Ciguatoxins	Ciguatoxins affects the expression of INHBA mRNA	18353800
C034211	cinnabar	cinnabar results in increased expression of INHBA protein	25629042
D002945	Cisplatin	Cisplatin results in increased expression of INHBA mRNA	21151649
D002945	Cisplatin	Cisplatin results in decreased expression of INHBA mRNA	22023808
D003035	Cobalt	[tungsten carbide co-treated with Cobalt] results in decreased expression of INHBA mRNA	18078969
D005576	Colforsin	FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]	18936084
D005576	Colforsin	INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]	18936084
D003436	Croton Oil	Croton Oil results in increased expression of INHBA mRNA	19647056
D000242	Cyclic AMP	Cyclic AMP results in increased secretion of INHBA protein	20074812
D016572	Cyclosporine	Cyclosporine results in decreased expression of INHBA mRNA	22147139; 27989131;
D000077209	Decitabine	Decitabine results in increased expression of INHBA mRNA	27915011
D003907	Dexamethasone	Dexamethasone results in decreased expression of INHBA mRNA	25047013
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of INHBA mRNA	28628672
D003907	Dexamethasone	Dexamethasone results in decreased expression of INHBA mRNA	22733784
D016264	Dextran Sulfate	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INHBA mRNA	29950665
D003913	Dextroamphetamine	Dextroamphetamine results in increased expression of INHBA mRNA	12205029; 12558987;
D003913	Dextroamphetamine	SOD1 inhibits the reaction [Dextroamphetamine results in increased expression of INHBA mRNA]	12205029
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of INHBA mRNA	21266533
D004041	Dietary Fats	Dietary Fats results in decreased expression of INHBA mRNA	30120929
D004041	Dietary Fats	Dietary Fats results in increased expression of INHBA mRNA	21852083
D004041	Dietary Fats	Resveratrol inhibits the reaction [Dietary Fats results in increased expression of INHBA mRNA]	21852083
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in increased expression of INHBA mRNA	31163220
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of INHBA mRNA	29505797
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of INHBA mRNA	19850644
D004051	Diethylhexyl Phthalate	PPARA protein promotes the reaction [Diethylhexyl Phthalate results in decreased expression of INHBA mRNA]	19850644
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of INHBA mRNA	28943392
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased expression of INHBA mRNA	17255206
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased expression of INHBA protein	17255206
D004054	Diethylstilbestrol	Diethylstilbestrol promotes the reaction [FSHB protein results in increased expression of INHBA mRNA]	15878960
C012125	diisononyl phthalate	diisononyl phthalate results in decreased expression of INHBA mRNA	22112501
C015835	dimethyl-4-toluidine	dimethyl-4-toluidine results in decreased expression of INHBA mRNA	27638505
D004137	Dinitrochlorobenzene	Dinitrochlorobenzene results in increased expression of INHBA mRNA	19647056
C516138	dorsomorphin	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
D004317	Doxorubicin	Doxorubicin affects the expression of INHBA mRNA	29803840
D004317	Doxorubicin	INHBA protein affects the susceptibility to Doxorubicin	16217747
D004726	Endosulfan	Endosulfan results in decreased expression of INHBA mRNA	29391264
C118739	entinostat	entinostat results in increased expression of INHBA mRNA	26272509
C118739	entinostat	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in increased expression of INHBA mRNA	20876846
D004958	Estradiol	Estradiol results in increased expression of INHBA mRNA	20876846
D004958	Estradiol	4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]	20660070
D004958	Estradiol	[Estradiol co-treated with IL1B protein] results in increased expression of INHBA mRNA	17636213
D004958	Estradiol	[Estradiol co-treated with IL1B protein] results in increased secretion of [INHBA protein binds to INHBA protein]	17636213
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA	20660070
D004958	Estradiol	[Estradiol co-treated with TGFB1 protein] results in increased expression of INHBA mRNA	30165855
D004958	Estradiol	Estradiol results in decreased expression of INHBA mRNA	21177794; 23373633;
D004958	Estradiol	IL11 protein promotes the reaction [INHBA protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]]	20074812
D004958	Estradiol	INHBA protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]	20074812
D004958	Estradiol	INHBA protein promotes the reaction [IL11 protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]]	20074812
D004958	Estradiol	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]	20660070
D004958	Estradiol	pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]	20660070
D004958	Estradiol	Estradiol results in decreased expression of INHBA mRNA	17255206
D004958	Estradiol	Estradiol results in decreased expression of INHBA protein	17255206
D004958	Estradiol	Estradiol results in increased expression of INHBA mRNA	22285243
D004958	Estradiol	Estradiol results in increased expression of INHBA mRNA	15972882
D000431	Ethanol	Ethanol results in decreased expression of INHBA mRNA	19167417
D000431	Ethanol	Ethanol results in increased expression of INHBA mRNA	30319688
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of INHBA mRNA	17555576
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of INHBA mRNA	17942748
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of INHBA mRNA	17942748
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of INHBA mRNA	15834898; 28522409;
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of INHBA mRNA	23129252
D005054	Eugenol	Eugenol results in decreased expression of INHBA mRNA	15618236
D005557	Formaldehyde	Formaldehyde results in increased expression of INHBA mRNA	27664576
C069837	fullerene C60	fullerene C60 results in decreased expression of INHBA mRNA	19167457
C039281	furan	furan results in decreased expression of INHBA mRNA	25539665; 26194646;
C001277	geldanamycin	geldanamycin results in increased expression of INHBA mRNA	26705709
D019833	Genistein	Genistein results in decreased expression of INHBA mRNA	22228119
D019833	Genistein	Genistein results in decreased expression of INHBA protein	22228119
D019833	Genistein	INHBA protein affects the susceptibility to Genistein	22228119
D006108	Graphite	Graphite affects the expression of INHBA mRNA	29933104
C031927	hydroquinone	hydroquinone results in increased expression of INHBA mRNA	31256213
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of INHBA mRNA	28628672
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of INHBA mRNA	25613284
D007529	Isoflavones	Isoflavones results in decreased expression of INHBA mRNA	16365062
C561695	(+)-JQ1 compound	[(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of INHBA mRNA	25119042
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of INHBA mRNA	24796395; 25119042;
D007649	Ketamine	Ketamine results in decreased expression of INHBA mRNA	20080153
C008261	lead acetate	lead acetate results in increased expression of INHBA mRNA	20542052
D008070	Lipopolysaccharides	Triclosan inhibits the reaction [Lipopolysaccharides results in increased expression of INHBA mRNA]	20507366
D008344	Maneb	[Maneb co-treated with Paraquat] results in decreased expression of INHBA mRNA	23017109
D008344	Maneb	[Paraquat co-treated with Maneb] affects the expression of INHBA mRNA	22563483
D008727	Methotrexate	Methotrexate affects the expression of INHBA mRNA	18502557
C005223	methyleugenol	methyleugenol results in decreased expression of INHBA mRNA	15618236
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of INHBA mRNA	23179753; 27188386;
D015735	Mifepristone	Mifepristone results in increased expression of INHBA mRNA	17584828
C583365	N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide	N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide results in decreased expression of INHBA mRNA	29244179
C078131	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]	20660070
D037742	Nanotubes, Carbon	Nanotubes, Carbon analog results in increased expression of INHBA mRNA	20800606
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in decreased expression of INHBA protein	23634900
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in increased expression of INHBA mRNA	23634900; 25511174;
D037742	Nanotubes, Carbon	Nanotubes, Carbon analog results in increased expression of INHBA mRNA	25554681
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in increased expression of INHBA mRNA	25554681; 25620056;
D009288	Naproxen	Naproxen inhibits the reaction [Capsaicin results in increased expression of INHBA protein]	22150557
C051752	nefazodone	nefazodone results in decreased expression of INHBA mRNA	24136188
D009355	Neomycin	Neomycin results in increased expression of INHBA mRNA	30626089
C022838	nickel chloride	nickel chloride results in increased expression of INHBA mRNA	17312168
C029938	nickel sulfate	nickel sulfate results in increased expression of INHBA mRNA	16780908
C012655	nimesulide	nimesulide results in decreased expression of INHBA mRNA	24136188
C007350	nitrofen	nitrofen results in decreased expression of INHBA mRNA	26720608
D018817	N-Methyl-3,4-methylenedioxyamphetamine	N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of INHBA mRNA	20188158
C025589	ochratoxin A	ochratoxin A results in increased expression of INHBA mRNA	23358140
D010076	Oxazepam	Oxazepam results in decreased expression of INHBA mRNA	15618236
D010081	Oxazolone	Oxazolone results in increased expression of INHBA mRNA	19647056
C472349	oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine	oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine affects the expression of INHBA mRNA	17655762
C472349	oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine	oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine promotes the reaction [Particulate Matter affects the expression of INHBA mRNA]	17655762
C472349	oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine	oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine promotes the reaction [Vehicle Emissions affects the expression of INHBA mRNA]	17655762
C472349	oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine	Particulate Matter promotes the reaction [oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine affects the expression of INHBA mRNA]	17655762
C472349	oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine	Vehicle Emissions promotes the reaction [oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine affects the expression of INHBA mRNA]	17655762
D010100	Oxygen	Oxygen deficiency results in decreased expression of INHBA mRNA	20660070
D010100	Oxygen	Oxygen deficiency results in increased expression of INHBA mRNA	20042640; 26516004;
D010100	Oxygen	[NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of INHBA mRNA	30529165
D010126	Ozone	[Ozone co-treated with Chlorine] results in increased expression of INHBA mRNA	18636392
D010269	Paraquat	[Maneb co-treated with Paraquat] results in decreased expression of INHBA mRNA	23017109
D010269	Paraquat	[Paraquat co-treated with Maneb] affects the expression of INHBA mRNA	22563483
D010269	Paraquat	Paraquat results in increased expression of INHBA mRNA	22563483
D010269	Paraquat	Paraquat results in decreased expression of INHBA mRNA	17077588
D052638	Particulate Matter	oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine promotes the reaction [Particulate Matter affects the expression of INHBA mRNA]	17655762
D052638	Particulate Matter	Particulate Matter affects the expression of INHBA mRNA	17655762
D052638	Particulate Matter	Particulate Matter promotes the reaction [oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine affects the expression of INHBA mRNA]	17655762
C568608	PCI 5002	[PCI 5002 co-treated with Zinc] results in increased expression of INHBA mRNA	18593933
C506614	PD 0325901	[(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of INHBA mRNA	25119042
C031375	pepstatin	pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]	20660070
C101814	perfluoro-n-undecanoic acid	perfluoro-n-undecanoic acid results in increased expression of INHBA mRNA	23602845
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in decreased expression of INHBA mRNA	19162173
D010629	Phenformin	Phenformin results in decreased expression of INHBA mRNA	31324951
D010634	Phenobarbital	Phenobarbital results in decreased expression of INHBA mRNA	19270015; 23091169;
D010662	Phenylmercuric Acetate	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
C006253	pirinixic acid	[pirinixic acid co-treated with PPARA] results in decreased expression of INHBA mRNA	20813756
C006253	pirinixic acid	pirinixic acid results in decreased expression of INHBA mRNA	20813756; 23811191;
C006253	pirinixic acid	pirinixic acid results in decreased expression of INHBA mRNA	19162173; 22112501;
D010938	Plant Oils	Plant Oils results in increased expression of INHBA mRNA	23370395
C060540	polyhexamethyleneguanidine	polyhexamethyleneguanidine results in increased expression of INHBA mRNA	24583197
D059808	Polyphenols	Polyphenols results in decreased expression of INHBA mRNA	16293270
D011192	Potassium Dichromate	Potassium Dichromate results in decreased expression of INHBA mRNA	23608068
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in increased expression of INHBA mRNA	20876846
D011374	Progesterone	4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]	20660070
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA	20660070
D011374	Progesterone	FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]	18936084
D011374	Progesterone	GDF9 protein inhibits the reaction [INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]]	20660033
D011374	Progesterone	GDF9 protein inhibits the reaction [INHBA protein results in decreased secretion of Progesterone]	20660033
D011374	Progesterone	IL11 protein promotes the reaction [INHBA protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]]	20074812
D011374	Progesterone	INHA mutant form inhibits the reaction [GDF9 protein inhibits the reaction [INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]]]	20660033
D011374	Progesterone	INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]	18936084
D011374	Progesterone	INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]	20660033
D011374	Progesterone	INHBA protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]	20074812
D011374	Progesterone	INHBA protein promotes the reaction [IL11 protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]]	20074812
D011374	Progesterone	INHBA protein results in decreased secretion of Progesterone	20660033
D011374	Progesterone	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]	20660070
D011374	Progesterone	pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]	20660070
D011374	Progesterone	[Progesterone co-treated with IL1B protein] results in increased expression of INHBA mRNA	17636213
D011374	Progesterone	[Progesterone co-treated with IL1B protein] results in increased secretion of [INHBA protein binds to INHBA protein]	17636213
D011374	Progesterone	Progesterone results in decreased expression of INHBA mRNA	18070364; 20660070;
D011374	Progesterone	Progesterone results in increased expression of INHBA mRNA	17636213
D011374	Progesterone	Progesterone results in increased secretion of [INHBA protein binds to INHBA protein]	17636213
D011374	Progesterone	Progesterone results in increased expression of INHBA mRNA	22285243
D011374	Progesterone	INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]	17954979
C005556	propionaldehyde	propionaldehyde results in decreased expression of INHBA mRNA	26079696
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of INHBA mRNA	24780913
C428725	pyridaben	pyridaben results in increased expression of INHBA mRNA	22563483
D020849	Raloxifene Hydrochloride	[Raloxifene Hydrochloride co-treated with ESR2 protein] results in increased expression of INHBA mRNA	19059307
D000077185	Resveratrol	Resveratrol results in increased expression of INHBA mRNA	11588890
D000077185	Resveratrol	Resveratrol inhibits the reaction [Dietary Fats results in increased expression of INHBA mRNA]	21852083
D012402	Rotenone	Rotenone results in decreased expression of INHBA mRNA	28374803
C078903	seocalcitol	seocalcitol results in decreased expression of INHBA mRNA	12040012
D000077149	Sevoflurane	Sevoflurane affects the expression of INHBA mRNA	15967596
D012822	Silicon Dioxide	Silicon Dioxide analog results in increased expression of INHBA mRNA	25895662
D012822	Silicon Dioxide	Silicon Dioxide results in increased expression of INHBA mRNA	22300531; 25351596;
D012834	Silver	Silver results in decreased expression of INHBA mRNA	27131904
C009277	sodium arsenate	sodium arsenate results in decreased expression of INHBA mRNA	16882884
C017947	sodium arsenite	sodium arsenite results in decreased expression of INHBA mRNA	29301061
C017947	sodium arsenite	sodium arsenite results in increased expression of INHBA mRNA	20020861
C016104	sodium bichromate	sodium bichromate results in decreased expression of INHBA mRNA	25993096
D018170	Sumatriptan	Sumatriptan inhibits the reaction [Capsaicin results in increased expression of INHBA protein]	22150557
D000077210	Sunitinib	Sunitinib results in decreased expression of INHBA mRNA	31533062
D013629	Tamoxifen	[Tamoxifen co-treated with ESR2 protein] results in increased expression of INHBA mRNA	19059307
D013629	Tamoxifen	Tamoxifen affects the expression of INHBA mRNA	17555576
D000077204	Temozolomide	INHBA mRNA affects the susceptibility to Temozolomide	16365179
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in increased expression of INHBA mRNA	15336504
D013739	Testosterone	[FSHB protein co-treated with Testosterone] results in increased expression of INHBA mRNA	18535249
D013739	Testosterone	[PRKACA protein mutant form co-treated with Testosterone] results in increased expression of INHBA mRNA	18535249
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of INHBA mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of INHBA mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of INHBA mRNA	19770486
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of INHBA mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased secretion of INHBA protein	26572662
D013749	Tetrachlorodibenzodioxin	AHR protein alternative form affects the reaction [Tetrachlorodibenzodioxin results in decreased expression of INHBA mRNA]	21215274
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of INHBA mRNA	22298810
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of INHBA mRNA	21215274
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of INHBA mRNA	25613284
D019284	Thapsigargin	Thapsigargin results in increased expression of INHBA mRNA	21694771
D013853	Thioacetamide	[Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of INHBA mRNA	28943392
D013853	Thioacetamide	Thioacetamide results in decreased expression of INHBA mRNA	23411599
C009495	titanium dioxide	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INHBA mRNA	29950665
C009495	titanium dioxide	titanium dioxide results in decreased expression of INHBA mRNA	23557971
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of INHBA protein	30291989
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of INHBA mRNA	30291989
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of INHBA mRNA	20133372
D014051	Toluene 2,4-Diisocyanate	Toluene 2,4-Diisocyanate results in increased expression of INHBA mRNA	19647056
D019772	Topotecan	INHBA protein affects the susceptibility to Topotecan	16217747
C483909	torcetrapib	torcetrapib results in increased expression of INHBA mRNA	23228038
D014212	Tretinoin	Tretinoin results in decreased expression of INHBA mRNA	20530235
D014212	Tretinoin	Tretinoin results in increased expression of INHBA mRNA	21934132
D014212	Tretinoin	[bis(4-hydroxyphenyl)sulfone co-treated with Tretinoin] results in decreased expression of INHBA mRNA	30951980
D014212	Tretinoin	[bisphenol A co-treated with Tretinoin] results in decreased expression of INHBA mRNA	30951980
D014212	Tretinoin	[bisphenol F co-treated with Tretinoin] results in decreased expression of INHBA mRNA	30951980
C011559	tributyltin	tributyltin results in decreased expression of INHBA mRNA	29505797
C012589	trichostatin A	trichostatin A results in increased expression of INHBA mRNA	26705709
D014260	Triclosan	Triclosan inhibits the reaction [Lipopolysaccharides results in increased expression of INHBA mRNA]	20507366
C002802	tungsten carbide	[tungsten carbide co-treated with Cobalt] results in decreased expression of INHBA mRNA	18078969
D014635	Valproic Acid	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA	27188386
D014635	Valproic Acid	Valproic Acid results in decreased methylation of INHBA gene	29154799
D014635	Valproic Acid	Valproic Acid results in increased expression of INHBA mRNA	19101580; 24383497; 26705709; 28001369;
D014635	Valproic Acid	Valproic Acid results in decreased expression of INHBA mRNA	24535564
D014635	Valproic Acid	Valproic Acid results in decreased expression of INHBA mRNA	29427782
D000068756	Valsartan	Valsartan inhibits the reaction [AGT protein results in increased expression of INHBA mRNA]	19225232
D014638	Vanadates	Vanadates results in increased expression of INHBA mRNA	22714537
D001335	Vehicle Emissions	oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine promotes the reaction [Vehicle Emissions affects the expression of INHBA mRNA]	17655762
D001335	Vehicle Emissions	Vehicle Emissions affects the expression of INHBA mRNA	17655762
D001335	Vehicle Emissions	Vehicle Emissions promotes the reaction [oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine affects the expression of INHBA mRNA]	17655762
D001335	Vehicle Emissions	Vehicle Emissions results in decreased methylation of INHBA gene	25560391
D014747	Vinblastine	INHBA protein affects the susceptibility to Vinblastine	16217747
D014800	Vitallium	Vitallium analog results in increased expression of INHBA mRNA	23825117
D014801	Vitamin A	[Vitamin A co-treated with INHBA protein] results in decreased expression of SHH mRNA	17244017
D014801	Vitamin A	[Vitamin A co-treated with INHBA protein] results in increased expression of GCG mRNA	17244017
D014801	Vitamin A	[Vitamin A co-treated with INHBA protein] results in increased expression of INS1 mRNA	17244017
D014801	Vitamin A	[Vitamin A co-treated with INHBA protein] results in increased expression of INS2 mRNA	17244017
D014801	Vitamin A	[Vitamin A co-treated with INHBA protein] results in increased expression of PDX1 mRNA	17244017
D014801	Vitamin A	[Vitamin A co-treated with INHBA protein] results in increased expression of PPY mRNA	17244017
D014801	Vitamin A	[Vitamin A co-treated with INHBA protein] results in increased expression of PTF1A mRNA	17244017
D014801	Vitamin A	[Vitamin A co-treated with INHBA protein] results in increased expression of SOX17 mRNA	17244017
D014801	Vitamin A	[Vitamin A co-treated with INHBA protein] results in increased expression of SST mRNA	17244017
D015025	Zearalenone	Zearalenone results in decreased expression of INHBA mRNA	30138655
D015025	Zearalenone	Zearalenone results in increased expression of INHBA mRNA	25455459
D015032	Zinc	[PCI 5002 co-treated with Zinc] results in increased expression of INHBA mRNA	18593933

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0165	Cleavage on pair of basic residues
KW-1015	Disulfide bond
KW-0325	Glycoprotein
KW-0339	Growth factor
KW-0372	Hormone
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0964	Secreted
KW-0732	Signal

Interpro

InterPro ID	InterPro Term
IPR029034	Cystine-knot_cytokine
IPR000491	Inhibin_betaA
IPR001839	TGF-b_C
IPR001111	TGF-b_propeptide
IPR015615	TGF-beta-rel
IPR017948	TGFb_CS

PROSITE

PROSITE ID	PROSITE Term
PS00250	TGF_BETA_1
PS51362	TGF_BETA_2

Pfam

Pfam ID	Pfam Term
PF00019	TGF_beta
PF00688	TGFb_propeptide

Gene: INHBA

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction